| Survival: | 10.5 months |
| Toxicity Grade: | 3 |
| Treatments: | Biologic therapy Chemotherapy |
| Drugs: | Mitozytrex Platinol |
| Country: | United Kingdom |
| City/State/Province: | Sutton |
| Hospital: | The Royal Marsden Hospital |
| Journal: | Link |
| Date: | 2/2002 |
| Description: |
| Patients: This Phase I study involved 13 patients with malignant mesothelioma. Treatment: The treatment consisted of a suspension of heat-killed Mycobacterium vaccae (SRL172), a fast growing avirulent mycobacterium, that may have non-specific immunomodulating properties in combination with standard chemotherapy (mitomycin-C (mitozytrex), vinblastine (velban) and cisplatin (platinol)). Toxicity: Grade 1-3 toxicities included infection, emesis, mucositis, diarrhea, constipation, alopecia, neuropathy, fatigue, and hematological. Results: The median overall survival was 10.5 months. Support: This study was supported by a research grant from SR Pharma. SR Pharma markets SRL172. Correspondence: MER O’Brien, MD |